2.27
3.18%
+0.07
After Hours:
2.27
Oramed Pharmaceuticals, Inc stock is currently priced at $2.27, with a 24-hour trading volume of 113.65K.
It has seen a +3.18% increased in the last 24 hours and a -19.79% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $2.24 pivot point. If it approaches the $2.33 resistance level, significant changes may occur.
Oramed Pharmaceuticals, Inc Stock (ORMP) Financials Data
Oramed Pharmaceuticals, Inc (ORMP) Revenue 2024
ORMP reported a revenue (TTM) of $2.70 million for the quarter ending June 30, 2023, a +0.22% rise year-over-year.
Oramed Pharmaceuticals, Inc (ORMP) Net Income 2024
ORMP net income (TTM) was $5.53 million for the quarter ending December 31, 2023, a +115.11% increase year-over-year.
Oramed Pharmaceuticals, Inc (ORMP) Cash Flow 2024
ORMP recorded a free cash flow (TTM) of -$10.55 million for the quarter ending December 31, 2023, a +62.87% increase year-over-year.
Oramed Pharmaceuticals, Inc (ORMP) Earnings per Share 2024
ORMP earnings per share (TTM) was $0.14 for the quarter ending December 31, 2023, a +114.89% growth year-over-year.
Oramed Pharmaceuticals, Inc Stock (ORMP) Latest News
About Oramed Pharmaceuticals, Inc
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule for the treatment of diabetes; and ORMD-0901, an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes. It is also developing a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
Cap:
|
Volume (24h):